We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01462565
First Posted: October 31, 2011
Last Update Posted: October 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
  Purpose
The purpose of this multicentre, open label, single-arm study in approximately 20 adult patients is to evaluate the Impact on lifestyle of a new thermo stable formulation of epoprostenol sodium in subjects with Pulmonary Arterial Hypertension (PAH).

Condition Intervention Phase
Hypertension, Pulmonary Drug: current marketed FLOLAN (epoprostenol sodium) Drug: new thermo stable formulation of epoprostenol sodium Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36) [ Time Frame: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 (Visit 3) ]
    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores was considered as better health status. Change from Baseline was calculated as score at observation minus score at baseline. Baseline was defined as Visit 2 i.e. Day-14 (+ or - 7 days).

  • Change From Baseline in Study Specific Participant Acceptance Survey [ Time Frame: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 (Visit 3). ]
    Study-specific questionnaire comprised the pre-defined15 questions which included activities of daily living assessment. Participants rated the question on a scale of 1 to 10, where 1 was do not agree and 10 was strongly agree. Change from Baseline was calculated as score at observation minus score at Baseline. Changes from Baseline was assessed for Questions 2 to 12. Baseline was defined as Visit 2 i.e. Day-14 (+ or - 7 days).

  • Change From Baseline in Dose of Thermo Stable Epoprostenol Sodium at Week 4 [ Time Frame: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 ]
    Dose titration requirement was assessed at the time of discharge. Change from Baseline was calculated as score at observation minus score at Baseline. Units- nanogram per kilogram per minute (ng/kg/min). Baseline was Visit 2 i.e . Day-14 (+ or - 7 days).


Secondary Outcome Measures:
  • Number of Participants With Any Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events(SAEs) [ Time Frame: Up to visit 3 (Week 4) ]
    An AE was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, congenital anomaly/birth defect and medically significant and all events of possible drug-induced liver injury with hyperbilirubinaemia. Only treatment emergent AEs and SAEs were reported in this outcome measure. Specifically, this study reported 2 SAEs, but only 1 was categorized as treatment emergent.

  • Number of Participants With Infusion Site Reactions During Treatment Period [ Time Frame: Baseline visit (Visit 2) to Week 4 (Visit 3) ]
    Infusion site reactions were reported during the treatment period. Infusion site was inspected for erythema, excoriation, induration, skin necrosis or signs of local sepsis.

  • Change From Baseline in Vital Signs at Week 4 : Systolic and Diastolic Blood Pressure [ Time Frame: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4(Visit 3) ]
    Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Change from Baseline was calculated as the value at the indicated time points minus the value at Baseline. Baseline was Visit 2 i.e. Day-14 (+ or - 7 days).

  • Change From Baseline in Vital Signs at Week 4: Heart Rate [ Time Frame: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) to Week 4 ]
    Summary mean change in heart rate measured in beats per minute (beats/min or BPM). Change from Baseline was calculated as the value at the indicated time points minus the value at Baseline. Baseline was Visit 2 i.e. Day-14 (+ or - 7 days).

  • Number of Participants With Abnormal Clinical Chemistry [ Time Frame: Up to 1 week after Week 4 (Follow-up) ]
    Abnormal clinical chemistry was analyzed as follows: serum alanine aminotransferase (ALT/SGPT) >= 3 x upper limit of normal (ULN) , aspartate aminotransferase (AST/SGOT) >= 3 x ULN , total bilirubin >= 34.2, creatinine >= 176.8.

  • Number of Participants With Abnormal Hematology [ Time Frame: Up to 1 week after Week 4 (Follow-up) ]
    Values for hemoglobin, hematocrit, and platelet count were analyzed. Participants with abnormal values have been reported. The low and high value concern were as follows: hemoglobin (Males < 98, >180.0) (females <91, >161.0)grams per litre (g/L); hematocrit (Males < 32.0, >54.0) (females <29.0, >50.6) fraction (1); platelet count (< 100, > 500) gram international units per litre (gI/L).

  • Number of Participants With Abnormal Urinalysis [ Time Frame: Up to 1 week after Week 4 (Follow-up) ]
    Dipstick method was used to measure blood, glucose and protein. Data was analyzed up to 1 week after Week 4 (Follow-up visit).

  • Change From Baseline in Six Minute Walk Distance Test (6MWD) After 4-weeks of Treatment [ Time Frame: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 ]
    This assessment was a non-encouraged test that measures the distance walked for a duration of 6 minutes. Change from Baseline was calculated as value at observation minus value at Baseline. Baseline visit was Visit 2 i.e. Day-14 (+ or - 7 days).

  • Breathlessness After 6MWD - Borg Dyspnoea Index (BDI) [ Time Frame: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) to Week 4 ]
    The BDI was calculated by using a 10-point scale (0 = None, 10 = Maximum) and indicates the degree of breathlessness after completion of the 6-minute walk test. The BDI scale was assessed by each participant. Change from Baseline = score at observation minus score at Baseline. Baseline visit was Visit 2 i.e. Day-14 (+ or - 7 days).

  • World Health Organization [WHO] Functional Class at Baseline and After 4- Weeks of Treatment [ Time Frame: Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 ]
    World Health Organization functional class was analyzed as class I, class II, class III and class IV. World Health Organization functional class was analyzed at Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4. The classed were defined as Class I: No symptoms of pulmonary arterial hypertension with exercise or at rest, Class II: No symptoms at rest but uncomfortable and short of breath with normal activity, Class III: May not have symptoms at rest but activities greatly limited by shortness of breath, fatigue, or near fainting and Class IV: Symptoms at rest and severe symptoms with any activity. Hence the severity increased from class I (better) to Class IV (worse).

  • Mean Oxygen Saturation in Blood Over Time [ Time Frame: up to the treatment follow up (1 week after Visit 3 [Week 4]) ]
    Pulse oximetry (oxygen saturation) was analyzed. Data for Pulse oximetry (oxygen saturation) was analyzed up to the treatment follow up (1 week after Visit 3 [Week 4]).

  • Number of Participants With Urine Pregnancy Test Positive [ Time Frame: up to the treatment follow up (1 week after Visit 3 [Week 4]) ]
    Urine samples were collected for urine pregnancy test. Urine samples were collected at up to the treatment follow up (1 week after Visit 3 [Week 4]). Number of participants with urine pregnancy test positive has been reported.


Enrollment: 16
Study Start Date: November 1, 2011
Study Completion Date: November 8, 2012
Primary Completion Date: May 16, 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: All subjects
Subjects enter the study already taking current marketed FLOLAN (epoprostenol sodium) and continue for 4 weeks (run-in). At baseline, they will be swopped to the new thermo stable formulation of epoprostenol sodium for 4 weeks (or longer if they continue in the extension phase of the study).
Drug: current marketed FLOLAN (epoprostenol sodium)
continuous intravenous infusion
Drug: new thermo stable formulation of epoprostenol sodium
continuous intravenous infusion

Detailed Description:

This is a multicentre, open label, single-arm study in approximately 20 adult patients (18 - 75 years old) designed to evaluate the Impact on lifestyle of a new thermo stable formulation of epoprostenol sodium in subjects with Pulmonary Arterial Hypertension (PAH). The co-primary objectives are 1) to describe the effect of the new thermo stable formulation of epoprostenol sodium on quality of life and 2) to determine the dose titration requirement in patients switching from the currently marketed FLOLAN (epoprostenol sodium) to the new thermo stable formulation. Secondary objectives include assessing the safety, tolerability and efficacy of the thermo stable formulation of epoprostenol sodium and the exploratory objective is to evaluate the effect of the new thermo stable formulation of epoprostenol sodium on haemodynamic parameters in a subset of subjects.

Subjects who are already receiving FLOLAN (epoprostenol sodium) for the treatment of PAH and have been on a stable dose for at least 3 months and on stable doses of other PAH treatments for at least 30 days prior to screening will be enrolled. After a screening visit, eligible subjects will have a 4-week run-in period with their existing FLOLAN (epoprostenol sodium) treatment. At the end of the 4-week period, they will be admitted to the clinic for baseline assessments and for switching to study medication (the new thermo stable formulation of epoprostenol sodium). Subjects will remain in hospital for a minimum of 6 hours to ensure clinical and hemodynamic stability prior to discharge. Subjects may stay in hospital for up to 24-48 hours after switching to the new thermo stable formulation of epoprostenol sodium at the discretion of the investigator. Dose titration requirement will be assessed at the time of discharge. Haemodynamic parameters will be obtained in a subgroup of subjects enrolled in centres where the collection of haemodynamic data is considered part of the standard of care. Subjects will receive the study medication as a continuous intravenous infusion for a 4-week treatment period. Those who complete the 4-week treatment period will have the option of entering an extension phase of the study to continue receiving the new formulation.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult male or female at least 18 to 75 years at the time of screening.
  • Subjects must have been on FLOLAN (epoprostenol sodium) therapy for pulmonary arterial hypertension (PAH) as approved in the product label.
  • Subjects must be on stable doses of their existing FLOLAN (epoprostenol sodium) treatment for a minimum of 3 months prior to screening.
  • Subjects must be on stable doses of any current PAH treatments other than FLOLAN (epoprostenol sodium) in the last 30 days.
  • Subjects must walk a distance of at least 150 meters during six-minute walk distance test (6MWD). This test must be completed during the Screening Visit.
  • A female subject is eligible to participate if she is of non-childbearing potential or of childbearing potential, has a negative pregnancy test at screen, and agrees to use one of the contraception methods listed in the protocol.
  • Subjects must be competent to understand the information given in the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved informed consent form and must sign the form prior to the initiation of any study procedures.

Exclusion Criteria:

  • Subjects who are given FLOLAN (epoprostenol sodium) for a condition or in a manner that is outside the approved indication.
  • Subjects with congestive heart failure arising from severe left ventricular dysfunction.
  • Subjects, with or without supplemental oxygen, who have a resting arterial oxygen saturation (SaO2) <90% as measured by pulse oximetry at screening.
  • Subjects have been hospitalized as an emergency or visited the emergency room for a condition related to PAH or treatment for PAH in the last 3 months.
  • The subject's clinical condition is such that they are not expected to remain clinically stable for the duration of the study.
  • Female subjects who are pregnant or breastfeeding.
  • Subjects who have demonstrated noncompliance with previous medical regimens.
  • Subjects who have a history of abusing alcohol or illicit drugs within 1 year.
  • Subjects with a diagnosis of active hepatitis (hepatitis B surface antibody and hepatitis C antibody).
  • Subjects who have participated in a clinical study involving another investigational drug or device within four weeks before screening.
  • Subjects who had history malignancies within the past 5 years, with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix.
  • Any concurrent condition that would affect the safety of the subject or in the opinion of the investigator it is not in the best interest of the patient to participate in the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01462565


Locations
United States, Florida
GSK Investigational Site
Miami Beach, Florida, United States, 33140
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60637
United States, Maryland
GSK Investigational Site
Baltimore, Maryland, United States, 21205
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02118-2393
United States, Ohio
GSK Investigational Site
Columbus, Ohio, United States, 43221
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75390-8550
Canada
GSK Investigational Site
Quebec, Canada, G1V 4G5
Netherlands
GSK Investigational Site
Amsterdam, Netherlands, 1081 HV
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01462565     History of Changes
Other Study ID Numbers: 115332
First Submitted: October 13, 2011
First Posted: October 31, 2011
Results First Submitted: May 22, 2017
Results First Posted: October 16, 2017
Last Update Posted: October 16, 2017
Last Verified: May 2017

Keywords provided by GlaxoSmithKline:
flolan
pulmonary arterial hypertension
thermo stable formulation
epoprostenol sodium
modified sterile diluent

Additional relevant MeSH terms:
Hypertension
Familial Primary Pulmonary Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Epoprostenol
Tezosentan
Antihypertensive Agents
Platelet Aggregation Inhibitors
Vasodilator Agents